As of 2025-02-14, the Relative Valuation of Myriad Genetics Inc (MYGN) is (26.50) USD. This relative valuation is based on P/E multiples. With the latest stock price at 14.65 USD, the upside of Myriad Genetics Inc based on Relative Valuation is -280.9%.
The range of the Relative Valuation is (22.32) - (30.38) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
Range | Selected | |
Trailing P/E multiples | 14.4x - 23.8x | 16.8x |
Forward P/E multiples | 17.5x - 25.4x | 24.8x |
Fair Price | (22.32) - (30.38) | (26.50) |
Upside | -252.4% - -307.3% | -280.9% |
Date | P/E |
2025-02-07 | -9.74 |
2025-02-06 | -9.99 |
2025-02-05 | -10.15 |
2025-02-04 | -9.74 |
2025-02-03 | -10.02 |
2025-01-31 | -9.94 |
2025-01-30 | -10.13 |
2025-01-29 | -9.84 |
2025-01-28 | -9.81 |
2025-01-27 | -10.17 |
2025-01-24 | -10.06 |
2025-01-23 | -10.01 |
2025-01-22 | -9.64 |
2025-01-21 | -9.87 |
2025-01-17 | -9.72 |
2025-01-16 | -9.83 |
2025-01-15 | -10.32 |
2025-01-14 | -10.74 |
2025-01-13 | -11.21 |
2025-01-10 | -11.64 |
2025-01-08 | -11.60 |
2025-01-07 | -11.22 |
2025-01-06 | -10.81 |
2025-01-03 | -10.73 |
2025-01-02 | -10.60 |
2024-12-31 | -10.76 |
2024-12-30 | -10.70 |
2024-12-27 | -10.53 |
2024-12-26 | -10.60 |
2024-12-24 | -10.78 |
2024-12-23 | -10.71 |
2024-12-20 | -10.49 |
2024-12-19 | -10.34 |
2024-12-18 | -10.40 |
2024-12-17 | -10.85 |
2024-12-16 | -11.08 |
2024-12-13 | -11.33 |
2024-12-12 | -11.38 |
2024-12-11 | -11.39 |
2024-12-10 | -12.04 |
2024-12-09 | -11.68 |
2024-12-06 | -11.87 |
2024-12-05 | -12.84 |
2024-12-04 | -13.03 |
2024-12-03 | -12.74 |
2024-12-02 | -13.10 |
2024-11-29 | -12.77 |
2024-11-27 | -12.78 |
2024-11-26 | -12.69 |
2024-11-25 | -12.33 |